More Than Just a Barrier: The Immune Functions of the Airway Epithelium in Asthma Pathogenesis

Andreas Frey1,2, Lars P. Lunding2,3, Johanna C. Ehlers2,4, Markus Weckmann2,5, Ulrich M. Zissler6,7 and Michael Wegmann2,3*

1 Division of Mucosal Immunology and Diagnostics, Research Center Borstel, Borstel, Germany, 2 Airway Research Center North, German Center for Lung Research (DZL), Borstel, Germany, 3 Division of Asthma Exacerbation & Regulation, Research Center Borstel, Borstel, Germany, 4 Division of Experimental Pneumology, Research Center Borstel, Borstel, Germany, 5 Department of Pediatric Pulmonology and Allergology, University Children’s Hospital, Lübeck, Germany, 6 Center of Allergy & Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany, 7 Member of the German Center for Lung Research (DZL), CPC-M, Munich, Germany

Allergic bronchial asthma is a chronic disease of the airways that is characterized by symptoms like respiratory distress, chest tightness, wheezing, productive cough, and acute episodes of broncho-obstruction. This symptom-complex arises on the basis of chronic allergic inflammation of the airway wall. Consequently, the airway epithelium is central to the pathogenesis of this disease, because its multiple abilities directly have an impact on the inflammatory response and thus the formation of the disease. In turn, its structure and functions are markedly impaired by the inflammation. Hence, the airway epithelium represents a sealed, self-cleaning barrier, that prohibits penetration of inhaled allergens, pathogens, and other noxious agents into the body. This barrier is covered with mucus that further contains antimicrobial peptides and antibodies that are either produced or specifically transported by the airway epithelium in order to trap these particles and to remove them from the body by a process called mucociliary clearance.

Once this first line of defense of the lung is overcome, airway epithelial cells are the first cells to get in contact with pathogens, to be damaged or infected. Therefore, these cells release a plethora of chemokines and cytokines that not only induce an acute inflammatory reaction but also have an impact on the alignment of the following immune reaction. In case of asthma, all these functions are impaired by the already existing allergic immune response that per se weakens the barrier integrity and self-cleaning abilities of the airway epithelium making it more vulnerable to penetration of allergens as well as of infection by bacteria and viruses. Recent studies indicate that the history of allergy- and pathogen-derived insults can leave some kind of memory in these cells that can be described as imprinting or trained immunity. Thus, the airway epithelium is in the center of processes that lead to formation, progression and acute exacerbation of asthma.

Keywords: asthma, inflammation, barrier, mucus, polarization, imprinting, trained immunity
INTRODUCTION

With more than 300 million people affected bronchial asthma is one of the most common chronic inflammatory diseases worldwide (1). Actually, 1 out of 250 deaths is associated with asthma and it causes annual direct medical (drugs, care, hospitalization) and indirect economic (productivity loss, early retirement) costs of about €34 Billion for the EU (2) and over 80 Billion for the United States (3, 4), making it a major burden for public healthcare systems (5).

Asthma is characterized by acute broncho-obstruction, in combination with additional symptoms such as cough, chest tightness, shortness of breath, and wheezing, which vary in extent and over time. These symptoms arise on the basis of chronic airway inflammation in response to a trigger, most commonly inhaled allergen(s), that causes airway hyperresponsiveness (AH), airway remodeling and mucus hypersecretion (6). Due to the complexity and variation of the symptoms along with its pathogenesis, asthma is nowadays described as a heterogeneous syndrome with distinct sub- or endotypes. However, the majority of asthma patients displays allergic inflammation of the airways, which can be classified by profiles of several characteristic mediators in “TH2 high” or “TH2 low” subtypes (7). Thus, in sensitized individuals T helper 2 (TH2) cells orchestrate allergic inflammation by releasing a typical array of cytokines including interleukins (IL)-4, -5, -9, and -13 and granulocyte-macrophage colony stimulating factor (GM-CSF). These mediators induce the production of allergen-specific immunoglobulin (Ig) E, TH2 cell development, goblet cell differentiation, submucosal gland activity, as well as recruitment, maturation, and activation of eosinophils and its precursors (8). Activation of mast cells and eosinophils via IgE-bound allergens results in their degranulation and, thus, in the release of a plethora of effector molecules and growth factors that on the one hand destroy airway tissue and on the other hand conduct its repair. Chronic activation of these processes ultimately lead to signs of airway remodeling such as increased smooth muscle mass, subepithelial fibrosis, and epithelial desquamation, which in turn give rise to the pathological changes and clinical symptoms characteristic for asthma (9).

Allergic sensitization against aeroallergens represents the strongest factor predisposing for the development of asthma, indicating a hyperreaction of the immune system to be the central event within the pathogenesis of this disease. Nevertheless, structural cells and particularly airway epithelial cells also appear to be of critical importance. This is not surprising since these cells represent the barrier that first encounters environmental stress factors like air pollutants, bacterial and viral pathogens, as well as allergens, and markedly contributes to their neutralization by a mechanism called mucociliary clearance (MCC). Besides these barrier and cleaning functions airway epithelial cells also exert a number of immunological tasks interweaving the role of the epithelium with that of the above-mentioned cells of the immune system. Here we aim to review these immune functions of the airway epithelium against the background of asthma pathogenesis.

THE BARRIER FUNCTION OF THE AIRWAY EPITHELIAL CELL LAYER ITSELF

The main purpose of mucosae is to separate the body from its environment and therefore they are essential for the maintenance of the inner homeostasis. Though this task is not commonly regarded as an “active” or “typical” immune function, it is absolutely central for the defense against allergens, pathogens and other harmful environmental factors. In order to fulfill this function the airway epithelium forms a continuous, self-cleaning barrier with a considerable resistance against biological, chemical or physical stressors (10). Together with the physical barriers of the MCC and glycocalyx, this is achieved by three types of intercellular epithelial junctions that form the structural adhesion forces of the airway mucosa by linking the intracellular structures of the cytoskeleton of one epithelial cell to that of its neighbors. These junctions involve adherens junctions (AJs), hemidesmosomes, and tight junctions (TJs).

AJs can appear as spots (adhesion plaques) or as bands encircling the cell (zonula adherens). In the junctional zone AJs interconnect the actin filaments of the adherent cells via homotypic transmembrane E-cadherin adhesions and anchor proteins like actinin, vinculin, and α-, β-, and p120 catenins, while adhesion plaques attach the cells to the extracellular matrix (11).

Similarly, hemidesmosomes are focal structures that form adhesive bonds between the cytoskeleton of epithelial cells and the lamina lucida, which is a part of the lamina propria. Hemidesmosomes utilize integrin α6β4, plectin 1a and the tetraspanin CD151 connecting laminin and fibronectin of the extracellular matrix to the intermediate filaments of the cytoskeleton (12).

In contrast, TJs form a multiprotein junctional complex called zonula occludens (ZO) that in turn appears as the main regulator of the paracellular permeability. These complexes are formed by several transmembrane and cytoplasmic proteins that are attached to actin filaments of the cytoskeleton. The main components of TJs are claudins and occludins, proteins with four transmembrane domains, as well as so-called junctional adhesion molecules (JAMs) belonging to the immunoglobulin superfamily with only one transmembrane domain. These proteins are connected to actin filaments by cingulin and ZO proteins 1, -2, and -3 (13).

In the airways of healthy individuals, the TJs of the zonula occludens and AJs of the zonula adherens constitute dense protein networks that interconnect the basolateral sides of epithelial cells in such a way that they prevent the paracellular passage of basically all molecules, including water, ions and proteins, as well as of pathogens or other inhaled particulate matter. Several findings strongly indicate that in asthma patients the barrier function is impaired by epithelial disruption. For example, endobronchial biopsies revealed a fragile or even
injured airway mucosa with partially or completely uncovered areas and detachment of columnar, ciliated cells (14). Epithelial desquamation is further indicated by the presence of epithelial cells in bronchoalveolar lavage (BAL) and of creola bodies (epithelial cell aggregates) in sputum of asthmatics (15). Furthermore, bronchi biopsies of asthmatic subjects displayed patchy disruption of TJ's (16) and the expression of a number of proteins that are essential for the formation of TJ's and AJ's has been shown to be markedly reduced. Among these proteins are a-catenin (17), b-catenin (18), occluding (16), ZO-1 (16, 17), and E-cadherin (17, 19). The levels of the latter one in sputum also correlate with asthma severity (20). These data are further supported by in vitro studies where primary bronchial epithelial cells are kept in air liquid interface (ALI) culture, a method that allows the cells to differentiate and form a pseudo-stratified epithelial monolayer largely resembling the physiological structure of the airway mucosa. Once this structure has been established, in vitro barrier integrity can be assessed by measuring the transepithelial electrical resistance (TEER), a characteristic that is indicative of the tightness of a cell layer (21). Several studies showed that ALI cultured airway epithelia from asthma patients display a decreased TEER in comparison to epithelia derived from healthy controls (16, 22, 23).

IMPAIRED FUNCTION IN ASTHMA PATHOGENESIS

To date, three different factors are discussed to have a harmful impact on the barrier integrity of the airway epithelium in asthma pathogenesis: allergens themselves, viral infection, and (allergic) inflammation. According to the “protease hypothesis” allergens with an inherent protease activity are capable of cleaving the protein components of the aforementioned intercellular epithelial junctions so that the barrier function is disrupted and allergens can penetrate the airway mucosa on the paracellular route, which eventually could result in sensitization against them. Accordingly, a considerable number of allergens has been tested in vitro for proteolytic potential and for an effect on epithelial barrier integrity. Several studies provided evidence for a direct cleavage of e.g., occludin and ZO-1 proteins by the major allergen from house dust mites (Dermatophagoides), Der p 1 (24, 25). House dust mite extracts as well as Der p 1 have been shown to increase the permeability and to decrease TEER of epithelial layers in vitro (23, 25, 26). Comparable effects have been shown for extracts of the allergenic fungus Alternaria alternata that reduced TEER of human bronchial epithelial cells in vitro (27) or the Aspergillus fumigatus-derived alkaline protease 1 (Alp-1) (28). Similarly, a variety of different pollen extracts has been investigated for their effect on the barrier integrity of epithelial cells in vitro. Diffusates of Italian cypress (Cupressus sempervirens), Orchard grass (Dactylis glomerata), Olive (Olivia europaea), and Scots pine (Pinus sylvestris) have been shown to affect claudin-1, E-cadherin, and occludin expression and thus to disrupt epithelial junctions in ALI cultures of Calu-3 cells, an effect which could be suppressed by protease inhibitors (29). Japanese hop (Humulus japonicus) extract also reduced expression of occludin in a comparable setting (30). Another study provided evidence for proteolytic activity of Giant ragweed (Ambrosia trifida), Kentucky bluegrass (Poa pratensis), and White birch (Betula pendula) as shown by reduced expression of claudin-1, occludin, and ZO-1 in Calu-3 as well as in MDCK cells (31). However, an inherent protease activity appears not to be the only way, by which allergens can impair the barrier integrity of the airway epithelium. Cockroach, HDM, fungus, and mold extracts have also been shown to activate the protease-activated receptor (PAR-1) and/or 2, which in turn leads to degradation of AJ components (25, 32–34).

The effect of viral infections on airway barrier function is even more pronounced than that of allergens. Respiratory viruses cause junction dysfunction by different mechanisms: human rhinovirus (HRV), respiratory syncytial virus (RSV), human metapneumovirus (HMPV), influenza and parainfluenza viruses bind to their entry receptor, which are typically protein or sugar structures expressed on the cellular surface for other purposes, leading to endocytosis of the virus. Once the virus has been internalized, it uncoats and initiates the viral replication process, which has certain consequences for infected cells. On the one hand, the cell starts with the production of type I interferons (IFN) in order to slow down the internal virus replication and to activate the cellular immune response against the virus. In consequence, infected airway epithelial cells are killed by virus-specific, cytotoxic CD8 + T cells. On the other hand, the virus itself also kills epithelial cells, since it induces morphological alteration of the cells summarized as cytopathic effect (CPE). For HRV and influenza viruses, the CPE manifests in rounding and detachment of airway epithelial cells that are ultimately lysed by the virus in order to release freshly produced viruses. Paramyxoviruses such as RSV and HMPV induce cell fusion so that four or more cells form typical syncytia (35, 36). Additionally, at least HRV and RSV affect the barrier integrity of the airway epithelium by reducing the expression of epithelial junction proteins (37–40). It could be shown that HRV increases epithelial permeability by a reduction of occludin and ZO-1 expression (41, 42). RSV also disrupts junctional complex structures by fostering the activity of protein kinase D (PKD) (43).

The antiviral immune response also includes the release of cytokines that directly affect epithelial barrier function as well. This is especially true for IL-1b, IFN-γ and tumor necrosis factor (TNF). These cytokines have been shown to support epithelial permeability and to decrease expression of Claudins, JAM, occludin, and ZO-1 in several in vitro studies (44–46). In case of asthma, these effects are even more pronounced because of the allergic inflammatory response that already exists before the viral infection of the airway epithelium. Hence, TH2 type cytokines like IL-4 and IL-13 also increase barrier permeability by inhibiting the surface expression of b-catenin, E-cadherin, occludin, and ZO-1 (45, 47). In addition to cytokines, mast cell derived mediators also appear to have an effect on the barrier function of
the airway mucosa. Histamine for example has been shown to contribute to transient disruption of apical junctional complex integrity and thus to increase epithelial permeability in vitro (48).

Allergens, viruses, and the inflammatory response to their exposure represent extrinsic factors that impair the barrier integrity of the airway epithelium. However, some studies suggest that epithelial cells of asthma patients inherently predispose for an increased permeability. As already mentioned above, airway epithelial cells that have been isolated from asthmatics and propagated in vitro to form an epithelial monolayer under ALI culture conditions, display a decreased TEER as compared to cells from healthy donors (23, 45). This observation indicates that the cellular properties leading to an increased barrier permeability are somehow imprinted within the cells. Whether this is a matter of genetic predisposition encoded in epithelial stem cells or whether epithelial cells from asthma patients “remember” previous insults by epigenetic modifications that predispose for asthma development in later life remains elusive.

PASSIVE LUMINAL BARRIER STRUCTURE ON THE AIRWAY EPITHELIUM

Besides the barrier function of the epithelium provided by the mere presence of the sealed cell layer itself, two additional barrier structures are “exported” onto the luminal surface by the airway epithelium, a static one dubbed glycocalyx or periciliary layer (PCL) and a mobile one termed mucus.

STRUCTURE AND FUNCTION OF THE PERICILIARY LAYER

The glycocalyx or PCL is a sponge/fleece-like, cell membrane-anchored layer of glycolipids and glycoproteins – mainly mucins (see below) – that vertically stick out of the apical epithelial cell membrane. Although mainly attributed to the gut epithelium where it can extend up to 1500 nm (49) and to the vascular endothelium (50, 51) a glycocalyx/PCL is also present throughout the airway epithelium even down to the alveoli (52), again with heights up to 1500 nm in certain areas (53) (Figure 1). This static glycoprotein and glycolipid coat stores water to control mucus hydration but also serves as a protective zone against the compression of the mucus lying above in order to allow persistent cilia beating for ongoing functionality of the mucociliary clearance (MCC; see below) (53, 54). Beyond that, the glycocalyx/PCL regulates receptor specificity by architectural means and prevents the progression of viruses through the occasionally patchy mucus layer. It has been shown that the height and density of the epithelial glycocalyx can determine whether a ligand-equipped nanoparticle may attach to its membrane receptor or not (49, 55). In line with this, the inefficiency of adenovirus-mediated gene transfer into the airway epithelium was found to be caused by the membrane-tethered glycocalyx/PCL proteins that put a halt to the advance of the viral vectors (56, 57). Consequently, the susceptibility of the airway epithelium toward infection is at least to some extent controlled by the glycocalyx/PCL. Very small viruses such as bocavirus (HBoV1) and HRV, which are 20–30 nm in size (58, 59) should readily advance through the PCL to the epithelial plasma membrane as has been observed with nanoparticles of the respective size (53). Consequently, those viruses should be able to luminally infect airway epithelial cells as long as their receptor is present on the apical side. Little is known about receptor distribution in vivo but at least on cultured airway epithelial cells apical receptor expression and/or infectivity has been demonstrated for both viruses (60–63). Larger particles of about 100 nm and above, on the other hand, are efficiently blocked by the PCL (53). Hence, viruses such as RSV, HMPV, influenza and parainfluenza viruses, adenovirus or coronavirus, which are in this size range (64–67), should be hindered efficiently by the PCL to infect the host. Yet, those viruses often are associated with respiratory infections and asthma exacerbations (68, 69). One possibility for them to infect the airway epithelium may be the presence of the viral receptor on structures that extend from the PCL such as the tips of the cilia. An example for this is chemokine receptor CX3CR1 via which RSV can infect its host. In differentiated human airway epithelial cells this molecule is highly abundant on cilia (70, 71). Another possibility is the preceding action of a door-opener such as HBoV1 which may pave the way for further viral infections. HBoV1 was shown to persist for several months in the human airway epithelium (72) and causes pyroptotic cell death, epithelial cell hypertrophy, loss of cilia and disruption of the tight junction barrier (60, 61). Such a predamaged epithelial barrier may then readily fall victim to an influenza, parainfluenza or HPMV infection. With up to 13% of asthma exacerbations in small children found to be associated with HBoV1 infection (73) it may be worthwhile to further investigate possible coinfections with HBoV1 in asthma exacerbation cases. In this context, it may also be of interest that the treatment of chronic inflammatory diseases of the airways such as asthma with corticosteroids (CS) seems to reduce the glycocalyx/PCL height on the alveolar epithelium (74) thereby rendering the lung more susceptible to e.g., Pneumocystis carinii infection. Consequently, alleviating chronic inflammation in asthma with CS may make the patient more susceptible to certain infections, which in turn may enhance inflammation again, clearly a two-edged outcome of CS therapy in asthma.

Although the glycocalyx appears to be static on the architectural level, it may not be invariant in terms of its molecular composition. It was shown that lipopolysaccharide exposure could lead to heparan sulfate shedding from the airway epithelium thereby causing increased lung permeability (52). Allergen exposure of experimental animals resulted in different glycosylation patterns of the glycocalyx (75), which may result in a deviant presentation of viral and bacterial receptors on the cell surface. In light of the above, the airway epithelial glycocalyx seems to play a so far underestimated but possibly important role in airway epithelial defense. Whether or not the molecular composition
FIGURE 1 | Protection of epithelial surfaces by physical barriers. In the healthy state, ciliated cells (CC) form a tight epithelial layer where paracellular passage is prevented by sealing of lateral intercellular spaces with tight junctions (TJ). The apical epithelial cell surface, including the cilia, is covered by a layer of membrane-anchored glycoproteins and glycolipids, the glycocalyx. The dense meshwork of glycostructures restricts access of luminal matter to the apical cell surface; depending on their size, larger pathogens can be cut off from their receptor if it is not present on cilia (inset). Goblet cells (GC) secrete mucus, consisting of highly glycosylated mucins which absorb large quantities of water to form a viscous gel. The mucus – and any matter trapped within – is transported upward in the airway lumen by the coordinated beating of the cilia. BC, basal cells. In the asthmatic state, barrier functions can be compromised by partial disruption of tight junctions and gaps in the PCL/glycocalyx meshwork due to loss of cilia. Mucus clearance is impeded by increased mucus viscosity and swelling of the gel matrix, and by disturbance of ciliar beating due to disorganization and dykinesia of cilia.

COMPOSITION AND FUNCTION OF MUCUS

While the role of the glyocalyx/PCL is still subject of debate, the importance of mucus in airway luminal defense is unchallenged. Mucus is an unstirred discontinuous sheet of secreted mucous hydrogel which floats on top of the epithelium and is transported toward the oral cavity like the cargo on a conveyor due to the constant and coordinated beating of underlying ciliated cells (76). The mucus carried upward by this mucociliary clearance (MCC) mechanism can be swallowed or expectorated. As the mucus layer separates the airway lumen from the epithelium only objects that diffuse faster “vertically” toward the epithelial surface than the mucus is transported “horizontally” toward the oral cavity can reach the epithelial cell membranes. Thus, only nanoscalar objects and smaller, like gases, water, salts and nutrients are able to reach the epithelial cells (77, 78). This way the mucus carpet provides a protective line of defense against pathogens, dust and other harmful objects that might be inhaled by an individual. In addition to that, the sticky texture of the mucus slows down airborne objects and further prevents their advance to the epithelial cell layer. In order to exert these functions properly, mucus requires a specific composition. Mucus consists mainly of water, further components are salts, lipids and proteins. Among those, antimicrobial proteins like lysozyme, immunoglobulins and antimicrobial peptides are major molecular scavengers distributed within the mucus layer (79–81). The characteristic viscous, elastic and sticky properties of the mucus are provided by a group of macromolecules named mucins (82, 83).

To date, 21 genes coding for mucins have been described (84). Their protein products are secreted either to form mucus or remain immobile on the apical membranes of the airway epithelial cells where they become part of the glyocalyx/PCL. MUC5AC and MUC5B are the major secreted mucins in the airways. In addition, MUC2 and MUC19 are also part of airway mucus, albeit to a considerably smaller proportion, and thus belong to the family of secreted mucins (83). In contrast, MUC1, MUC4 and MUC16 are tethered to the cells of the airway epithelium (Figure 1) thereby contributing to the static luminal epithelial barrier, which resides underneath the mobile mucus layer (85, 86).

The viscous and elastic properties of the mucous gel are primarily given by the secreted polymeric mucins MUC5AC and MUC5B (83). These mucins are highly O-glycosylated proteins enriched with amino acids like proline, serine or threonine (87). Although both have a similar structure, MUC5B and MUC5AC differ in charge due to differential glycosylations (88). Their production depends on cell type and site of production. In the upper airways, MUC5AC is produced by epithelial goblet cells while MUC5B is secreted from mucous cells in
submucosal glands from secretory cells in the tracheal and bronchial epithelium. In the distal airways, MUC5B is also produced by secretory cells of the epithelium and seems to be the major mucin of this airway region (83, 89, 90). Before secretion, polymeric proteins are stored in secretory granules in a compacted, dehydrated state. Upon release, they switch to a hydrated form, which is necessary for the mucous gel-like properties (91, 92). Whether the two different mucins have different functions restricted to their site of production or whether the two mucins mingle to create a novel type of barrier structure is not clear yet. At least some studies analyzing airways of piglets have shown that MUC5B strands are becoming coated with MUC5AC to some extent after release at the epithelial surface (93, 94). A possible role of MUC2 and MUC19 has not been identified yet.

However, under healthy conditions, the viscous mucus traps noxious substances, which are then removed from the airway via ciliary beating by the MCC (95). In asthma, the MCC is impaired leading to mucus plug formation which in turn results in the characteristic obstruction observed in asthmatics. This is already a feature of mild stable asthma (∼98%) and the dysfunction worsens during aggravation of asthma and asthmatics. This is already a feature of mild stable asthma (96–98). One reason is an increased mucin content of the mucus thereby disturbing its regular composition. Normally, the airways’ mucus consists of ~98% water and only ~2% solid factors mainly mucins. In obstructive diseases, the amounts of mucins rise up to 8–15% (54, 86). Due to its hygroscopic nature, this leads to acquisition of static layer. The now protruding cilia either project into the mucus or get bend (54). Both effects impede passing on of the mucus to the next cell. Loss and/or disorientation of cilia as it is typical for asthmatics will further disturb the “bucket chain”-like transport process (99). On the cargo side enhanced intermolecular crosslinking of mucus constituents by oxidative processes may further complicate forwarding. It will also increase mucus viscosity eventually leading to plug formation. Oxidative intramolecular crosslinking of biomolecules is predominantly caused by cysteines whose thiol side chains can form disulfide bridges. All mucins are rich in cysteines, especially in their less glycosylated carboxy- and amino terminal regions. In the “normal” mucous gel of healthy individuals these cysteines are believed to be only moderately crosslinked, forming a lightly entangled network. In asthma, however, the degree of crosslinking and the density of the mucin network increases considerably (100, 101) (Figure 1). Increased oxidative stress appears to play an important role in this respect with eosinophils being the main suspects for oxidant production. The abnormally high levels of eosinophil peroxidase detected in the sputum of asthma patients may form an oxidative milieu. This would also bring the widely observed correlation between airway eosinophilia and airway obstruction into a causative relationship (102). Lastly, the MUC5AC of asthmatics tends to tether to the epithelium, which also complicates mucus forwarding (103).

In asthmatics not only the amount but also the composition of the mucus changes, especially the ratio of MUC5AC to MUC5B as well as the posttranslational modification of MUC5B. Mucus from healthy individuals contains predominantly MUC5B, which is essential for the MCC and protection against pathogens (104–106). In asthma, the proportion of MUC5B relative to MUC5AC often decreases (104, 105) along with the expression of a low-charge form of MUC5B. Consequently, there was a changed ratio between the two differently glycosylated forms of MUC5B (104, 107). The importance of MUC5B is indicated by Muc5b-deficient mice, which showed an accumulation of undesired substances e.g., bacteria, resulting in severe inflammation and airway obstruction (106).

The ratio between MUC5B and MUC5AC changes dramatically in asthma because MUC5AC expression and protein production are substantially upregulated in asthmatic patients (104, 105, 107). Especially patients with an eosinophilic type 2 asthmatic phenotype showed a shifted ratio toward higher MUC5AC concentrations (105, 108). This is in line with the assumption that MUC5AC seems to be important for the defense against enteric nematodal and influenza infections (109, 110). The increased expression of MUC5AC seems to depend on substantially increased levels of IL-13. The IL-13 signaling pathway activates the signal transducer and activator of transcription 6 (STAT6), which induces the expression of MUC5AC via various regulators (111) and appears to be involved in AHR development (112, 113). Several studies using in vitro systems with human epithelial cells or murine models validated this mechanism (114–117). Furthermore, EGFR, which is also overexpressed in asthma, also induces the expression of MUC5AC (118–121). This excessive production of mucins in the asthmatic airway epithelium leads to an increased volume of intracellular stored mucins, a mucus metaplasia (122). Thus, a higher number of goblet cells compared to the healthy situation appears in case of asthma (122). It is not exactly understood, whether this switch from a muco-ciliary phenotype to a mucous metaplastic phenotype develops from goblet cell hyperplasia, metaplasia or both as reviewed before (123). In animal models, goblet cell metaplasia/hyperplasia arises from an increased expression of primarily IL-13, but also of IL-4 and IL-9 (124–127). These cytokines are highly upregulated in asthmatic individuals (128–131). One important factor for the development of the goblet cell metaplasia is Notch2 regulated by IL-13 (132). Studies analyzing the function of SAM-pointed domain containing ETS transcription factor (SPDEF) highlighted its essential role in the development of goblet cell differentiation, hyperplasia and mucous metaplasia (133–135). Therefore, SPDEF seems to inhibit the expression of Forkhead box protein A2 (FOXA2) which is an important negative regulator of genes associated with mucous metaplasia and goblet cell hyperplasia (111, 121, 133, 136, 137).

Thus, the physical barriers provided by the airway epithelial layer seem to be deeply disturbed in asthmatic individuals. Although mucin is one of the most important barrier molecules in the airways its unbalanced overproduction is clearly detrimental to the desired outcome. Mucus plugging impedes egress of the active luminal defense molecules necessary to eliminate invaders.
ACTIVE LUMINAL DEFENSE MECHANISMS ON THE AIRWAY EPITHELIUM

Although strong walls (tight junctionally sealed epithelial cell layer) surrounded by a glacis (pericilial layer/glycocalyx) and a moat filled with flowing liquid (MCC) are crucial to prevent invaders from entering a castle, active defenses are necessary to end the siege. This is of particular importance when the besier can replicate and thus may increase continuously by number, as is the case when pathogenic bacteria colonize the luminal side of the airway epithelium.

DEFENSIVE MOLECULES PRODUCED BY THE EPITHELIUM

In order to get rid of a potential invader the airway epithelium possesses a battery of defense molecules, with which a potential microbial enemy can be attacked, destroyed or removed out of the airway lumen. Prominent innate molecular scavengers are lysozyme, transferrin and antimicrobial peptides. Lysozyme is produced in large amounts (20 mg/day) by serous cells of the upper human airway epithelium (138) and is able to destroy the polysaccharide capsules of many bacterial species. It has been shown that the production of lysozyme by serous cells residing in the serous glands of the upper airways is crucial for defending against bacterial airway invaders (139). Once the polysaccharide capsule is destroyed or damaged, so called defensins or antimicrobial peptides may exert the lethal hit to the invader. Defensins can form holes or pores into a bacterial cell membrane thereby killing a pathogen that aims to enter the body (79, 140, 141). In addition, lactoferrin is produced and secreted by serous cells (142), and transferrin is expressed by alveolar type I cells (143). These ferrins are iron-binding proteins, which deplete their environment from iron ions that are essential for the growth of a self-replicating organism (143, 144). Consequently, the pathogen is starved out.

THE ROLE OF SECRETORY IgA IN EPITHELIAL DEFENSE

Besides this innate “rapid response team,” the polarized epithelium of the human airways is also able to transport and apically release immunoglobulins that carry a J-chain (joining chain) by using its poly Ig receptor (pIgR) (145–147) that is expressed by all non-stratified epithelial cells (Figure 2). Only IgM and multimeric IgA are equipped with J-chains (148, 149). These two immunoglobulin classes not only circulate in the bloodstream but are also produced directly underneath the airway epithelium by B cells, given those lymphocytes express the J-chain (150, 151). Functionally, IgM can substitute for multimeric IgA. For that reason IgA-deficient individuals do not show a strong phenotype concerning susceptibility to infection. Nevertheless, secreted IgA (sIgA) outperforms IgM in terms of mucosal protection as it usually displays a higher affinity toward its antigen and, more importantly, is able to crosslink with mucins upon target binding (152, 153). This way an incoming viral or bacterial pathogen becomes trapped in mucus and is removed from the airway surface via the MCC. The protective function of secreted IgA has been demonstrated with various model systems, both for the gastrointestinal mucosa as well as for the airways, using passively administered monoclonal IgA (154–157), injected hybridoma cells whose target specific, dimeric IgAs are then transported across the mucosa ("backpack tumor model") (158–160) and by neutralization of preexisting mucosal IgA immunity with mucosally administered anti-IgA immunoglobulins (80). Although adaptive multivalent target binding via its hypervariable regions is probably the main mode of protection in those models, sIgA is also able to bind in an innate manner to luminal pathogens via its carbohydrate components by presenting decoy structures that mimic target cell surface receptors (161). If both modes of repelling fail and a pathogen has nonetheless invaded an epithelial cell, dimeric IgA may still be able to protect the infected cell, this time from inside. This is possible whenever the respective pathogen does not directly infect the cytosol of its target cell but rather uses an initial endocytosis step for infection. Depending on the infected organelle, vesicles, which concurrently translocate IgA toward the apical site, may fuse with the infected organelle, bind to the invader and carry it away into the lumen. In addition to this removal activity, mucus crosslinking and the tricking of pathogens by offering decoy receptors, sIgA also scavenges IL-8 and thereby inhibits IL-8-driven neutrophil chemotaxis (162).

In addition to these molecular interactions with a pathogenic target, IgA also binds to numerous cell types that patrol at the airway epithelium. The most important cellular partner seems to be the eosinophil as this cell possesses a total of five different receptors for IgA: FcR1 (CD89), transferrin receptor (TfR) (CD71), pIgR, asialoglycoprotein receptor (ASGPR) and a receptor for secretory component (SCR) with the integrin Mac-1 (CD11b/CD18) serving as a coreceptor for FcαR1 (163, 164). Depending on the receptor addressed and the form of IgA offered, i.e., soluble versus target-bound and cross-linked, eosinophils are either calmed down or activated (165-167). Yet, eosinophils are not only manipulated by IgA, they also influence IgA production themselves (168, 169). Thus, immunoglobulin A and eosinophils share a really intimate relationship.

Equipped with less receptors but still responsive to IgA are neutrophils, dendritic cells, macrophages, basophils and even epithelial lining cells that express the transferrin receptor such as alveolar-type 2 cells (170). An additional, so far unidentified receptor is present on M cells (microfold cells) (171, 172). M cells are a specialized epithelial lining cell type that is responsible for antigen sampling at mucosal surfaces and predominantly occurs in the epithelium above organized mucosa-associated lymphoid tissue (173, 174). This receptor senses the distance between two heavy chain domains in IgA. Thus, it is not able to bind IgA1, an IgA subclass present only in primates. IgA1 is different from IgA2 in that it contains a mucin-like, highly glycosylated
Release of immunoglobulin A at epithelial surfaces. Dimeric IgA is released submucosally by B cells and binds to the poly Ig receptor (plgR) which is found in high amounts in the basolateral membrane of the epithelium in the healthy state. The complex of plgR and dimeric IgA is transported in secretory vesicles to the apical side, where it is released into the lumen as secreted IgA (sIgA) to bind target antigens/allergens/pathogens and entrap them in mucus. In the asthmatic state, the amount of plgR in the epithelium appears to be reduced, resulting in diminished secretion of sIgA and futile accumulation of IgA in the subepithelial compartment.

extension of its hinge region. It is believed that this hinge region also serves as a ligand for yet other IgA receptors (163). If this holds true, subclass switching may be another adjusting wheel for IgA function. The class switch from IgA1 to IgA2 depends on the presence of the cytokines APRIL and BAFF which were shown to be produced by the epithelial layer itself, at least in case of the gut, upon bacterial stimulation (175). This way the microbiome as sparring partner of the epithelium comes into play as the true master of this adjusting wheel. In contrast to the gut where IgA2 prevails, IgA1 is the predominant IgA subclass in the airways (176). This, however, does not imply that IgA2 is of less importance for airway defense. IgA1 simply may be the first class formed after pathogen challenge. Those initial secretory IgA (sIgA) responses are believed to be not very mature. Upon pathogen challenge the human body apparently rapidly switches its current IgM repertoire to IgA even if most of such “first line of defense” IgA are of low affinity (177). This can be regarded as just a “better than nothing” attempt; yet it creates a window of opportunity for the body to develop more powerful sIgA via affinity maturation. Such optimized immunological scavengers are then able to block and eventually clear a microbial infection. Thus, the IgA system in which the transporting epithelium plays a key role is a complex defense machinery that combines innate with adaptive immune responses. It is therefore not surprising that the role of secretory IgA attracted attention in asthma research in recent years.

sIgA IN CHRONIC INFLAMMATION OF THE LUNG

The role of sIgA in chronic inflammatory lung diseases is still ambiguous. Some studies show that sIgA is necessary to maintain immune homeostasis, other reports claim that sIgA may play a detrimental role in asthma. A harmful effect of IgA in asthma may be explained by its ability to activate eosinophils and neutrophils because both cell types play a central role in the pathogenesis and persistence of asthma (178). When IgA is able to activate those cell types, this would readily lead to the hypothesis that in case of allergic asthma, allergen-specific IgA is responsible for this activation upon allergen exposure. This assumption is supported by the finding that increased levels of both, allergen-specific IgE and IgA were observed in the airway mucosa of patients with atopic asthma and/or rhinitis (179–183), and it was shown that allergen-specific IgA levels were positively correlated to eosinophil activation marker release after segmental lung challenge of asthmatic patients (166). Yet, coincidence and correlation do not necessarily imply a causative relationship.
In the abovementioned study, where a positive correlation of allergen-specific IgA and eosinophil activation was observed, the non-allergic control patients also displayed allergen-specific IgA in their airways; but in contrast, they did not have any allergen-specific IgE as was the case for asthmatics. Either so the allergen-specific IgE was responsible for eosinophil activation in asthmatics or the eosinophils of asthmatics underwent some kind of imprinting or immune training that rendered them more sensitive to allergen-specific IgA. With the expression of five different IgA receptors on the eosinophil described so far (163), locked-in differences in IgA receptor expression in eosinophils of asthmatics versus healthy individuals are not impossible. On the other hand, a coincidence of allergen-specific IgA and IgE does not necessarily imply a pathological role of IgA either. It may still be the case that IgA are beneficial to chronic airway inflammation, and the concomitant production of allergen-specific IgA can also be interpreted as a rescue attempt of the body to counteract the allergen-specific IgE.

In fact, more evidence points toward a beneficial role of IgA in asthma and other chronic airway inflammations. It was shown for instance that upon aging IgA knockout mice tend to develop chronic airway inflammation that resembles chronic obstructive pulmonary disease (COPD) in humans (184). A COPD-like phenotype also develops in plgR knockout mice upon exogenous bacterial challenge (185), and it has been shown in the past that COPD patients have an impaired plgR expression (186) and reduced slgA levels on the airway epithelium (187). Recently a similar phenomenon was reported for asthma (188) and rhinosinusitis (189). In the study of Ladjemi et al., asthmatics show a reduced immunostaining of pIgR in airway epithelia, and rhinosinusitis (189). In the study of Ladjemi et al., asthmatics show a reduced immunostaining of pIgR in airway epithelia, and reduced sIgA levels on the airway epithelium (187). In the abovementioned study, where a positive correlation of allergen-specific IgA and eosinophil activation was observed, the non-allergic control patients also displayed allergen-specific IgA in their airways; but in contrast, they did not have any allergen-specific IgE as was the case for asthmatics. Either so the allergen-specific IgE was responsible for eosinophil activation in asthmatics or the eosinophils of asthmatics underwent some kind of imprinting or immune training that rendered them more sensitive to allergen-specific IgA. With the expression of five different IgA receptors on the eosinophil described so far (163), locked-in differences in IgA receptor expression in eosinophils of asthmatics versus healthy individuals are not impossible. On the other hand, a coincidence of allergen-specific IgA and IgE does not necessarily imply a pathological role of IgA either. It may still be the case that IgA are beneficial to chronic airway inflammation, and the concomitant production of allergen-specific IgA can also be interpreted as a rescue attempt of the body to counteract the allergen-specific IgE.

A beneficial effect of allergen-specific IgA in the airway lumen was highlighted by Schwarze et al. (190). They showed that local application of a human monoclonal IgA antibody directed against the ragweed allergen Amb a attenuated the proinflammatory response to allergen inhalation in mice sensitized to Amb a I, whereas a control IgA against ovalbumin did not. Notably, the instilled anti-ragweed IgA induced the formation of Amb a 1-specific IgG2a in the animals upon allergen challenge which indicates a shift toward Th1. Thus, IgA residing in the airways may have an anti-allergic/anti-asthmatic immunomodulatory activity. This effect may be explained by the IgA feedback loop, via which a secretory IgA response is adjusted to current needs. In order to provide an optimal defense against luminal noxa luminal IgA are continuously sampled at the epithelium and transported to the basolateral side, where it is inspected by immune cells whether it is loaded with antigen or not. If this is the case, an immune response is mounted or boosted (191). Although this type of transcytotic event has been attributed primarily to M cells, the set-up of the ragweed-study rather precludes that route in this specific case in as much as a human IgA1 against Amb a I was used and this type of IgA does not bind to murine M cells (172). However, with a plethora of IgA receptors known, other epithelial cell types may have taken over the task. The IgA-binding transferrin receptor, for instance, is expressed by type II pneumocytes and was shown to transport transferrin conjugates to the basolateral site (192). In addition, similar to the gut, airway dendritic cells, which also carry IgA receptors, send protrusions to the epithelial layer via which luminal antigen can be sampled (193, 194). Yet, sampling antigen-loaded IgA from the airway lumen and driving the airway immune response toward Th1 requires the presence of IgA in the lumen, which is reduced by the Th2 micro-milieu in allergic asthma. This results in a vicious circle of a locked-in Th2 environment where a lack of IgA causes a further lack of IgA.

This is in line with clinical observations on asthmatic patients that suggests a critical role for IgA in asthma pathogenesis. Patients with selective IgA deficiency tend to bronchial hyperresponsiveness (195) and children that show a delay in maturation of IgA production display atopic manifestations more often (196). Moreover, immunotherapy against the respective aeroallergen result in higher specific mucosal Iga levels along with lower skin prick test sensitivity (197) or lower airway hyperreactivity (198). Nevertheless, most of the above suggests a prominent role of slgA or, more precisely, the lack thereof in the pathogenesis and chronicity of atopic asthma. Whether a lack of slgA also plays a prominent role in asthma exacerbations remains to be elucidated.

THE AIRWAY EPITHELIUM AS MEDIATOR OF AN ACUTE INFLAMMATORY REACTION

In addition to all the homeostatic defense functions like the maintenance of barrier integrity, transcytosis, and the mucosal clearance the airway epithelium also plays a major role against inhaled materials by producing several defense proteins such as mucins, defensins, antimicrobial peptides, cytokines, and chemokines (199). Thus, it contributes to local acute inflammatory reactions by regulating early inflammatory events via transcription and secretion of antimicrobial and pro-inflammatory proteins and by activating of mucin production (200, 201). Consequently, it is also a critical player during sensitization processes, asthma pathogenesis and acute exacerbations of the established disease (Figure 3).

DANGER AND PATHOGEN ASSOCIATED MOLECULAR PATTERN (DAMP AND PAMP) RECOGNITION BY PATTERN RECOGNITION RECEPTORS (PRR) OF THE AIRWAY EPITHELIUM

Inhaled pathogens that are not cleared by MCC are recognized by airway epithelial cells (202). Equipped with a large number of PRRs such as cytoplasmic NOD like receptors (NLR) and transmembrane toll like receptors (TLR) that can respond to
FIGURE 3 | Inflammatory response of the airway epithelium during stable allergic asthma and exacerbation. During stable allergic asthma airway epithelial cells (AECs) release IL-25, IL-33 and TSLP supporting differentiation of T helper (TH) 2 cells that are activated by dendritic cells (DCs). TH2 cells in turn secrete IL-5 and GM-CSF that together with AEC-derived eotaxins, RANTES and MCPs regulate the production, maturation, recruitment and activation of eosinophils. Local degranulation of eosinophils in the lung eventually leads to damage of the airway epithelium. In parallel, the TH2-type cytokines IL-9 and IL-13 induce goblet cell (GC) metaplasia in airway epithelium. During viral induced asthma exacerbations, several other additional factors lead to an aggravation of this inflammatory response. Viral infection can be detected by the airway epithelium via pattern recognition receptors (PRR). Subsequently, AECs secrete on the one hand TARC, the main chemokine for the recruitment of Th17 cells that amplifies the proinflammatory effects of Th2 cells via release of IL-17, and on the other hand IL-8, which leads to the recruitment of neutrophils. Local degranulation of neutrophils in the lung eventually leads to additional damage of the airway epithelium. Viral infection of AECs also directly leads to damage of the airway epithelium. In summary, these conditions result in a markedly increased damage of the airway epithelium compared to the stable disease, which further impairs barrier integrity and leads to release of matrikines further amplifying the ongoing inflammation.

DAMPs and PAMPs AECs represent the first line of cells, which can respond to pathogens and other danger signals like cell stress and cell death in the lung (203). DAMPs are molecules that are release from injured cells. Their presence is a clear sign for the loss of homeostatic integrity of specific cell compartments or even whole cells. Hence, they originate from the cytoplasm (S100 proteins, heat shock proteins, defensins, galectins, uric acid), the nucleus (High-Mobility-Group-Protein (HMGB1)), the endoplasmic reticulum (calreticulin), mitochondria (ATP, mitochondrial DNA, N-formylated peptides) or from the extracellular matrix (fibronectin, hyaluronan, versican) (204). Airway epithelial cells are both, responder to and producer of DAMPs (205, 206). The DNA binding protein HMGB1 for example, set free during necrosis of one cell can be detected from nearby cells by binding to their receptor AGE (RAGE), which leads to activation of nuclear factor kappa b (NFkB) and thereby to the production of pro-inflammatory mediators and consequently the recruitment of immune cells.

In turn, PAMPs are preserved molecules and structures from pathogens and toxins. They can originate from such different sources as bacteria, mycobacteria, viruses, fungi and parasites (207). PAMPs and DAMPs activate signaling pathways resulting in the transcription and production of cytokines and chemokines. In brief, signal transduction through MyD88 and MyD88-independent mechanisms leads to the activation of NFkB, mitogen-activated protein (MAP) kinases, and interferon regulatory factor (IRF) 3 (203). Based on the nature of the triggering PAMPs and DAMPs and a possible preexisting inflammatory environment in the lung its signals can result in protective effects or pathological effects for the host organism (208). Repeated cell stress and exposure to pathogens trigger chronic activation of PRR pathways in airway epithelial cells that are highly active and play an important role in chronic airways diseases (204).

PRR-TRIGGERED CYTOKINE AND CHEMOKINE REACTION OF THE AIRWAY EPITHELIUM

Activation of PRRs by DAMPs leads to a massive secretion of proinflammatory mediators like IL-6, CXCL8, TNF that consequently entail infiltration of activated immune cells. Some of these cells like dendritic cells (DC), lymphocytes and mast
cells are also involved in the pathogenesis of asthma (204, 209, 210). After contact for example with HDM extracts, representing a major source of asthma associated allergens, TLR4 dependent activation of NFκB and protease induced injuries in airway epithelial cells lead to secretion of chemokines and cytokines like thymic stromal lymphopoietin (TSLP), GM-CSF, IL-25, and IL-33 (211–215). This results in the activation and infiltration of DCs, innate lymphoid cells type 2 (ILC2) and Th2 cells (216–218).

During infection with bacterial pathogens airway epithelial cells can sense bacterial cell wall components via TLR2 (recognizing e.g., LTA), TLR4 (recognizing e.g., LPS), nucleotide-binding oligomerization domain-containing protein 1 (Nod1) and Nod2 (recognizing peptidoglycans) leading to activation of NFκB and subsequent immune responses and consequently to regulation of bacterial clearance (219, 220). Nucleic acid patterns arising during viral infection can be sensed via TLR3, TLR7/8, retinoic acid inducible gene 1 (RIG-1), and melanoma differentiation-associated protein 5 (MDA-5) (221–225). In response to TLR activation airway epithelial cells can also produce antimicrobial peptides such as human β-Defensin 2 (HBD-2) after TLR2 activation (201, 226).

The signals of different PRRs like TLRs, NLRs, and RAGE cooperate to regulate cellular immune responses to cell stress, infection and inflammation, which can amplify or dampen their effects (227).

Airway epithelial cells are very potent producers of cytokines and chemokines. The presence of aggressors like toxins and pathogens leads to production and fast and early secretion of IL-1β, IL-6, TNF, CXCL8, CCL11, and CCL20 (202, 228–230). Thereby, airway epithelial cells regulate and orchestrate local immunity by interacting with the recruitment of DCs, T-cells, and B-cells (CCL20), eosinophils (CCL11), and neutrophils (CXCL8). During viral infections they constitutively produce IFNβ to reduce viral replication and to support epithelial apoptosis (231). Thereby, airway epithelial cells represent the front line of antiviral defense mechanisms. As mentioned earlier, increased concentrations of proinflammatory cytokines like IL-1β, IL-4, IL-13, and TNF can directly lead to damage of the barrier function of the airway epithelium (44–47, 232, 233).

In allergic asthma airway epithelial cells are one of the main producers of proinflammatory cytokines and chemokines like IL-13, IL-33, TSLP, CCL5 (Rantes), CCL7 (MCP-3), CCL17 (TARC), CCL22, and several eotaxins. All of these cytokines strongly direct or support the development of a Th2 polarized inflammation (234). The chemokines CCL17 and CCL22 play a prominent role in the recruitment of Th2 cells by binding to the CCR4 receptor, since activation of it is a key event for Th2 cell specific chemotraction (235, 236). As a highly potent producer of TSLP the airway epithelium can create a local micro-milieu that supports and maintains a Th2 polarized inflammation (234, 237). In response to different epithelial injuries, airway epithelial cells secrete so-called alarmins like TSLP, IL-25, and IL-33 that direct T helper cell differentiation toward an Th2 phenotype (238). Additionally, secreted GM-CSF from airway epithelial cells leads to maturation and survival of eosinophils (239–241). Both effects are supporting allergic inflammation in asthma.

Taken together the airway epithelium plays a major role for the recognition of PAMPs and DAMPs in the lung. Binding of these molecules to their respective receptors enables the airway epithelium to regulate pathways important for barrier function, MCC and local immune responses. Functional disorders of the airway epithelium in the ability to answer the presence of PAMPs and DAMPs favor the development of chronic airways diseases. Viral infections and exposure to bacteria in early life modulate the acquisition of Th1 and Th2 immunity during further development and influence the responses to following exposures. These effects could play an even greater role in patients with asthma since they show disrupted MCC that could amplify the disease morbidity (242, 243). A cytokine induced Th2 polarization of the epithelium in combination with a barrier dysfunction induced by the same cytokines augments barrier impairment, further infiltration of proinflammatory cells, and enhanced penetration of inhaled allergens, which can be described as a self-reinforcing mechanism that predisposes for the development and perpetuation of allergic asthma (244–246).

Consequently, it has been suggested that an abnormal programming of the airway epithelium in general paired with an impaired capability to produce anti-inflammatory mediators such as IL-37 or α melanoctye stimulating hormone (α-MSH) may be the origin of chronic inflammatory airway diseases (247, 248).

THE AIRWAY EPITHELIUM IN VIRAL EXACERBATIONS OF ASTHMA

Viral infections of the airways is of critical importance for the pathogenesis of allergic bronchial asthma: On the one hand recurrent respiratory viral infections during early childhood represent one of the strongest factors increasing the risk for the development of asthma in later life (249–253). On the other hand such infections are by far the most common cause for acute exacerbation of already established asthma leading to acute aggravation of disease symptoms and necessitating increased medication, GP visits, and can lead to hospitalization and critical care measures under certain conditions (254). Indeed, the airway epithelium is in the center of action during such an exacerbation, since it is not only the barrier that first comes into contact with viral pathogens, but its cells are also the target for their infection and the site of their replication. Thus, viral infection of the airway epithelium does not only impair the barrier integrity as already mentioned before, but also triggers the release of chemokines, cytokines, alarmins, and matrikines of the epithelial layer that affect the pre-existing inflammatory response in the asthmatic airway, which largely contributes to the formation of an acute exacerbation.

The viruses that have been implicated in asthma pathogenesis and especially the formation of acute exacerbation are HRV, RSV, influenza and parainfluenza viruses, human metapneumovirus, corona and adenoviruses, however, HRV infections appear to be the most common cause (255, 256). HRV is a non-enveloped,icosahedral virus, which belongs to the family of picornaviridae (genus enterovirus) and is subdivided into three clades (A, B,
The single-stranded positive RNA genome of HRV is constituted of ca. 7200 nucleotides (257, 258). Clades A and B, which comprise the 100 most common serotypes, are further subdivided into a major and minor group. The major group utilizes the intracellular adhesion molecule-1 (ICAM-1) to bind to and transfect the host cell (259–261). The minor group HRV bind to the low density lipoprotein (LDL) receptor (262–265) and are considered to be more infectious. Clade C consists of 50 serotypes (266), which all bind to the cadherin-related family member 3 (CDHR3). All species of HRV have been shown to infect and replicate in airway epithelial cells (267).

Viral engagement with the specific receptor leads to transfection of the host cell (e.g., bronchial epithelial cells) and subsequently to a multitude of cellular responses. It is this cellular response that is believed to facilitate acute asthma exacerbation.

The cellular response to the virus is initiated by the detection of single-stranded RNA via TLRs -3, -7, and -8, MAD5, and RIG-I (221, 268). Activation of these receptors ultimately leads to the secretion of cytokines such as IL-1, IL-6, IL-8, IL-11, chemokines like CXCL10, CCL11 (eotaxin), CCL5 and anti-viral interferons of type I and III (268–274). The interferons have not only innate but also adaptive immune-system functionality to keep the viral infection locally at bay by mobilizing the adaptive immune response for effective viral clearance (275). Furthermore, proinflammatory cytokines like IL-1β and IL-6 are not specific for special types of immune response and thus, not only support the immune response against the invading virus but also promote the allergic immune response already established in the airways. Consequently, augmentation of the allergic immune response results in acute amplification of tissue damage, mucus production, and mediator release, and therefore in acute symptom aggravation.

Especially, the interferon response is thought to be an early post-infection event. In asthmatics epithelial interferon responses are believed to be hampered and as a consequence antiviral responses lack sufficient clearance (275). Not only interferons seem to be differently expressed in epithelial cells from asthmatics but also TSLP, which promotes Th2 responses (276). Another critical cytokine elevated in humans after HRV infections is IL-33, which also augments Th2 cell development (277).

**AIRWAY REMODELING IS A FEATURE OF HUMAN RHINOVIRUS INFECTION**

It is of note that viral infections not only initiate an immune response but also drive remodeling of the epithelial barrier and the subepithelial extracellular matrix (ECM). Hence, HRV16 induces perlecan, collagen V, tenasin c and matrix-associated (ma-) VEGF expression in an either TLR-3 or TLR-3/-7 associated manner in vitro (278, 279). Elevated expression of ma-VEGF and tenasin c was replicated in a mouse model of HRV infection, in which also Collagen I and fibronectin was found to be increased (278, 279). In addition, our group found human nasal epithelial cells infected with RV-16 in vitro to significantly downregulated genes associated with ECM receptor interaction and focal adhesion (280).

After infection and viral replication, the release of a vast array of mediators is among the earliest responses. In tissue culture a pneumocyte cell line expresses large amounts of IL-8 and CCL20 readily after 6 h post-infection (281). Also, the interferon response is thought to be an early post-infection event. In asthmatics epithelial interferon responses have been suggested to be hampered and as a consequence antiviral responses lack sufficient clearance (275). But not only interferons seem to be differently expressed in epithelial cells from asthmatics but also TSLP, which promotes Th2 responses (276). Another critical cytokine elevated in humans after HRV infections is IL-33. In line with that, Jackson et al. impressively showed, that the release of IL-33 by bronchial epithelial cells induces IL-4, IL-5, IL-13, and GATA3 expression in Th0 cells. An effect, which could be entirely blocked by an antibody against the IL-33 receptor (277).

Recently, active fragments from epithelial deposited ECM molecules have gained some recognition in asthma and asthma exacerbation. Matrikines are a class of molecules derived from ECM proteins (e.g., via proteolysis) with different properties from the parent molecule (282–284). In 2010, Burgess et al. reported diminished levels of the collagen IV isoform alpha 3 (COL4A3) in airways from asthmatic subjects. The non-collagenous domain of COL4A3 is referred to as tumstatin and a biologically active matrikine. Treatment of mice with experimental allergic asthma with human recombinant tumstatin let to a significant reduction of hallmark disease features (e.g., airway hyperresponsiveness, ma-VEGF, eosinophil influx, IL13) (285). In another study, Van der Velden et al. identified an anti-angiogenic effect of tumstatin in a sheep model of asthma (286). Further investigations revealed a novel active region in Tumstatin (CP17), which significantly reduced neutrophil influx, mucus production in a mouse model of viral asthma exacerbation and reduced migrational speed and production of reactive oxygen species of neutrophils in vitro (287, 288). While the matrikine tumstatin conveys protection from experimental features of asthma and asthma exacerbation, a collagen I derived matrikine (PGP, Acetylated-(Ac) PGP) has been shown to be a more potent inducer of neutrophil chemotaxis then IL-8 and is found to be increased in severe asthmatics, a group of patients prone to develop exacerbations (283, 289). Albeit ECM derived matrikines follow a different kinetical pathway (deposited first, released during inflammation) as compared to cytokines and chemokines (de novo production after viral infection), they can serve as protective or aggravating factors in asthma exacerbations.

In addition, the notion of epigenetic modification due to HRV infection in epithelial cells in asthma has gained attraction. McErlean et al. infected nasal epithelial cells from asthmatics and found evidence of reproducible changes to the methylome (290). We confirmed these results, which may unravel how asthmatic airway epithelial cells may be able to respond differently to the same stimuli as compared to healthy epithelial cells (280). First studies to investigate this effect in vivo are underway (291, 292).
E2-POLARIZED AIRWAY EPITHELIUM

Infection associated stimuli appear not to be the only factors that imprint mucosal immune reactions of the airway epithelium. In addition, the interaction between epithelial cells and leukocytes can lead to sustained alteration of respiratory epithelial cell biology. Even though these cells are definitely not able to constitute an immunological memory, it becomes more and more obvious that especially epithelial cells somehow memorize their exposure to certain environmental factors and the following insults and thereby develop some kind of trained immunity. We are just at the beginning to understand these processes and questions of which parts of the epithelium are trained and of how long the training effects sustain in the mucosa remain to be answered.

Thus, respiratory epithelial cells are constantly exposed to many types of challenges, including pathogens, allergens and environmental pollutants. Consequently, they are able to respond quickly and effectively to cellular damage such as the local cytokine production, lateral transport by ion exchanges, wide arrays of mucus compositions, secretion of antimicrobial peptides, and epithelial shedding. To date, it appears possible that different inflammatory environments as originated by for example typical Th1- or Th2-directed immune responses have a different impact on the biology of the respiratory epithelium and lead to some kind of E1- or E2-polarization of the respective epithelial cells (293) (Figure 4).

There is in vivo evidence for the inhibitory role of IFN-γ on asthma pathogenesis at the epithelial level indicating that type-1 responses counteract allergy (294, 295). The direct implication of airway epithelial cells was demonstrated by selective transgenic expression of the IFN-γ receptor on the airway epithelium and showed that IFN-γ inhibits mucus secretion, release of chitinases and eosinophilia independent of the activation of Th2 cells (296). In turn, GATA-3 inhibition causes an increase of T-BET and IFN-γ expression levels, leading to a dampened allergic phenotype (297). In addition, an increase in DNA-methylation of IFN-γ was observed during allergic sensitization (298), while perinatal prevention of allergy mediated by Acinetobacter does not show the anticipated drop in H4 acetylation in the IFN-γ promoter (299).

The immunological consequence of epithelial differentiation becomes increasingly interesting, as sensitization, but also recovery processes and airway remodeling could open new options for intervention and prevention of lung damage. Increasing evidence of mechanisms involving epithelial cytokine production such as CCL-26, and the epithelium-derived alarmins TSLP and IL-33 are substantiating the current focus on the cross talk between airway epithelium and immune cells in allergy research.

![Figure 4](https://example.com/figure4.png)

**FIGURE 4** | Mechanisms of allergic inflammation in epithelial cells. The role of tissue cells in the early phase of disease is largely unknown, but could provide important information about the pathologic development and could help to identify the causal relationships. However, bronchial epithelial cells are pre-committed to a type-2 (E2) or type-1 (E1) like phenotype. E2 epithelial cell activation by allergens takes place and their pro-inflammatory cytokines and chemokines induce inflammation and contribute to an epithelial type-2 response, so called “E2 response” with epithelial alarmins TSLP, IL-31, CCL-26, IL-25, and IL-33. Local type-2 responses involve multiple cytokines such as IL-4, IL-5, IL-9, IL-13, IL-25, IL-33, and increase of eosinophils. A series of chemokines are produced and migration of inflammatory cells to the allergic tissues takes place. The activation of e.g., smooth muscle cells by ADAM33 lead to remodeling. Bronchial hyperreactivity takes place leading to an enhanced susceptibility to bronchoconstriction. E1 epithelial cells respond to an infection releasing CXCL2, CXCL8, IL-12 and CCL20, thus stimulating the local synthesis of IFN-γ, IL-2, IL-12, IL-18, IL-36, and TNF-α that present a wide range of antiviral activities, inducing up-regulation of MHC-I molecules and antiviral resistance in uninfected cells. Neutrophils respond to the infection signals IL-12 and IFN-γ by releasing pro-inflammatory cytokines, leading to the containment of the infection, rise of body temperature and to the recruitment of further phagocytic cells.
However, it is unknown whether epithelial cells are influenced by IL-4 prior or with entry into terminal differentiation. This early influence could imprint the offspring cells that populate the epithelial surface and therefore have major consequences for the physiology of the airways. IL-4 was shown to have a major effect on the epithelium, as mice overexpressing this cytokine under the Club cell-secretory protein 10 (CC10) promoter show increased cellular infiltration, epithelial hypertrophy, mucus cell hyperplasia, secretion of gastric mucins and surfactant proteins (SP) A and B (300). While this model effectively demonstrated all hallmarks of experimental allergic asthma, it did not demonstrate whether IL-4 itself is inducing differentiation of basal cells or whether secondary effects trigger epithelial differentiation. However, the differentiation effects could also be observed in human primary epithelial cells of the nose, where IL-13 modulates the differentiation toward less ciliated and more secretory cells (114). To date, it is controversially discussed, whether IL-4 and IL-13 can also affect fully differentiated epithelial cells in air liquid-interphase cultures or whether this is only possible in immature submerged cultures (301, 302). However, during the epithelial differentiation process induced by air-liquid exposure, the addition of IL-4 enhances expression of certain antimicrobial peptides (303) and eicosanoids (304). Furthermore, it was demonstrated that IL-4 and IL-13, through inhibition of TLR3 expression and signaling (IRF3), impair immune responses to HRV infection (305). This is in line with the finding that chronic house dust mite exposure in the airways not only causes a strong Th2-directed inflammation but also diminishes anti-rhinovirus responses and local IFN expression, particularly of epithelial IFN-γ (306). In line with this, transgenic IL-4 expression in the lungs reduces cytotoxic T cell responses against Influenza viruses (307). On the level of secreted factors, it was shown that cytokines such as Wnt5a (Wingless-Type MMTV Integration Site Family, Member 5a) or CCL-26 or periostin were shown to be upregulated by IL-4 (Wingless-Type MMTV Integration Site Family, Member 5a) or of secreted factors, it was shown that cytokines such as Wnt5a.

---

**CONCLUSION**

In summary, the airway epithelium exerts a broad variety of immune functions that range from passive barrier over MCC, active production and transport of pathogen-neutralizing molecules to pathogen recognition and targeting as well as cytokine and chemokine release. The airway epithelium is usually the first tissue that is exposed to inhaled allergens, pathogens or pollutants. Since it is able to react on this contact by inducing local inflammatory reactions, it is clearly a central part of the local immune response and bridges innate and adaptive immune functions against all types of harmful intruders entering the respiratory system. Therefore, the airway epithelium is a key factor in asthma pathogenesis and plays a critical role in the development as well as in the progression and exacerbation of the disease: Hence, a disturbed cellular barrier enables allergens to enter the body and to induce a sensitization reaction, which is widely regarded as the starting point of an asthma career. Down the line, the protective mucus and PCL layers provided by the epithelium as physical barriers are compromised and the release of pathogen deterring molecules such as secretory immunoglobulins becomes impaired. As a consequence, this frontline toward invading pathogens can be breached and airway epithelial cells are infected and even destroyed by respiratory pathogens. A vicious cycle is started where barrier disturbance and infection promote each other. The latter, in particular with certain viruses, is also one of the strongest factors predisposing toward asthma development in early childhood.

Once asthma has been established, the airway epithelium responds to further viral infection with the release of manifold factors promoting not only the antiviral response but also augmenting the already present allergic inflammation and thus promoting acute asthma exacerbations. Finally yet importantly, it is also impaired and polarized by products released from cells of the chronified allergic immune response in the airways, which leads to impairment of mucus production, MCC, and the anti-inflammatory IFN-response in E2-polarized airway epithelial cells. Recent studies indicate that, in addition to this E2-polarization, also the history of allergy- and pathogen-derived insults does not only have a transient effect on the airway epithelium, but leaves some kind of memory in these cells that can be described as “imprinting” or “trained immunity.” Understanding the mechanisms underlying these processes would not only help to further understand the key role of airway epithelial cells in asthma pathogenesis but also could identify new targets for the treatment or even prevention of allergic asthma.
AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES

1. Network GA. The Global Asthma Report 2018. Auckland: Global Asthma Network (2018).
2. Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and disease in Europe: the new European Lung white book. *Eur Respir J.* (2013) 42:559–63.
3. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract.* (2017) 3:1.
4. Nurmiammetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008-2013. *Ann Am Thorac Soc.* (2018) 15:348–56.
5. Eder W, Eg MJ, von Mutius E. The asthma epidemic. *N Engl J Med.* (2006) 355:2226–35.
6. Taylor DR, Bateman, Boulet L-P, Boulet L-P, Boushey HA, Busse WW, Casale TB, et al. A new perspective on concepts of asthma severity and control. *Eur Respir J.* (2008) 32:545–54.
7. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Faby JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. *J Allergy Clin Immunol.* (2014) 133:386–94.
8. Fehrenbach H, Wagner C, Wegmann M. Airway remodeling in asthma: what really matters. *Cell Tissue Res.* (2017) 367:551–69.
9. Golony H, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. *Allergol Int.* (2018) 67:12–7.
10. Garcia MA, Nelson WJ, Chavez N. Cell-cell junctions organize structural and signaling networks. *Cold Spring Harb Perspect Biol.* (2018) 10.1101/cshperspect.a029181.
11. Rezaee F, Georas SN. Breaking barriers. New insights into airway epithelial barrier function. *Am J Respir Cell Mol Biol.* (2011) 45:1090–100.
12. Balenga NA, Klichinsky M, Xie Z, Chan EC, Zhao M, Jude J, et al. A fungal protease allergen provokes airway hyper-responsiveness in asthma. *Nat Commun.* (2015) 6:5763.
13. Buckley A, Turner JR. Cell biology of tight junction barrier regulation and signaling networks. *Cold Spring Harb Perspect Biol.* (2018) 10:029181.
14. Post S, Nawijn MC, Jonker MR, Kliphuis N, van der Berge M, van Post S, Nawijn MC, Jonker MR, Kliphuis N, van der Berge M, van Oosterhout AJM. Characterisation of cell adhesion in airway epithelial cell types using electric cell-substrate impedance sensing. *Eur Respir J.* (2010) 35:894–903. doi: 10.1183/09031936.00065809.
15. Leino MS, Loxham M, Blume C, Swindle EJ, Jayasekara NP, Dennison PW, et al. Barrier disrupting effects of alternaria alternata extract on bronchial epithelium from asthmatic donors. *PloS One.* (2013) 8:e71278. doi: 10.1371/journal.pone.0071278.
16. Balenga NA, Klichinsky M, Xie Z, Chan EC, Zhao M, Jude J, et al. A fungal protease allergen provokes airway hyper-responsiveness in asthma. *Nat Commun.* (2015) 6:5763.
17. Vinhas R, Cortes L, Cardoso I, Mendes VM, Manadas B, Todo-Bom A, et al. Pollen proteases compromise the airway epithelial barrier through degradation of transmembrane adhesion proteins and lung bioactive peptides. *Allergy.* (2011) 66:1088–98.
18. Lee SJ, Pham LD, Shin SY, Suh DH, Park H-S. Environmental changes could enhance the biological effect of Hop J polllons on human airway epithelial cells. *J Allergy Clin Immunol.* (2014) 134:470–2.
19. Runswick S, Mitchell T, Davies P, Robinson C, Garrod DR. Pollen proteolytic enzymes degrade tight junctions. *Respirology.* (2007) 12:834–42.
20. Winter MC, Shaby SS, Ries DR, Shaby DM. PAR2 activation interrupts E-cadherin adhesion and compromises the airway epithelial barrier: protective effect of beta-agonists. *Am J Physiol Lung Cell Mol Physiol.* (2006) 291:L628–35.
21. Jacquet A. Interactions of airway epithelium with protease allergens in the allergic response. *Clin Exp Allergy.* (2011) 41:305–11.
22. Li B, Zou Z, Meng F, Riaz E, Huang Y, Tao A, et al. Dust mite-derived Der f 3 activates a pro-inflammatory program in airway epithelial cells via PAR-1 and PAR-2. *J Mol Immunol.* (2019) 109:1–11. doi: 10.1016/j.molimm.2019.02.018.
23. Nam HK, Ison MG. Respiratory syncytial virus infection in adults. *BMJ.* (2019) 366:l5021. doi: 10.1136/bmj.l5021.
24. Soto JA, Gálvez NMS, Benavente FM, Pizarro-Ortega MS, Lay MK, Riedel C, et al. Human Metapneumovirus: mechanisms and molecular targets used by the virus to avoid the immune system. *Front Immunol.* (2018) 9:2466.
25. Singh D, McCann KL, Imani F. MAPK and heat shock protein 27 activation are associated with respiratory syncytial virus induction of human bronchial epithelial monolayer disruption. *Am J Physiol Lung Cell Mol Physiol.* (2007) 293:L436–45.
26. Comstock AT, Ganasan S, Chattoraj A, Faris AN, Margolis BL, Hershenson MB, et al. Rhinovirus-induced barrier dysfunction in polarized airway epithelial cells is mediated by NADPH oxidase 1. *J Virol.* (2011) 85:6795–808.
27. Faris AN, Ganasan S, Chattoraj A, Chattoraj SS, Comstock AT, Unger BL, et al. Rhinovirus delays cell repolarization in a model of injured/regenerating human airway epithelium. *Am J Respir Cell Mol Biol.* (2016) 55:487–99.
28. Looi K, Troy NM, Gurratt LW, Iosifidis T, Bosco A, Buckley AG, et al. Effect of human rhinovirus infection on airway epithelium tight junction protein disassembly and transepithelial permeability. *Exp Lung Res.* (2016) 42:380–95.
29. Rezaee F, DeSando SA, Ivanov AI, Chapman TJ, Knowelden SA, Beck LA, et al. Lactate, protein kinase D activation mediates respiratory syncytial virus-induced airway barrier disruption. *J Virol.* (2013) 87:11088–95.

FUNDING

This work was supported by the German Center for Lung Research (DZL).
42. Sajjan U, Wang Q, Zhao Y, Grunert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. Am J Respir Crit Care Med. (2008) 178:1271–81.

43. Rezaee F, Meednu N, Emo JA, Saatian B, Chapman TJ, Naydenov NG, et al. Polyinosinic:polyribidylic acid induces protein kinase D-dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells. J Allergy Clin Immunol. (2012) 128:1216–24.e1.

44. Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, Johnson LG. Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell. (2002) 13:3218–34.

45. Soyka MB, Wawrzynik P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. (2012) 130:1087–96.e10.

46. Hardyma MA, Wilkinson E, Martin E, Jaysakera NP, Blume C, Swindell EJ, et al. TNF-α-mediated bronchial barrier disruption and regulation by src-family kinase activation. J Allergy Clin Immunol. (2013) 132:665–75.e8.

47. Saatian B, Rezaee F, Desando S, Emo J, Chapman T, Knowlden S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers. (2013) 1:e2433. doi: 10.4161/tisb.24333.

48. Zabner J, Winter M, Excoffon KJDA, Stoltz D, Ries D, Shasby S, et al. Polyinosinic:polycytidylic acid induces protein kinase D-dependent cell death and disrupts the barrier function of polarized airway epithelial cells. J Biol Chem. (2009) 284:1216–24.

49. Oliveira MA, Zhao R, Lee WM, Kremer MJ, Ruckert RR, et al. The structure of human rhinovirus 16. Structure. (1993) 1:51–68.

50. Deng X, Yan Z, Luo Y, Xu J, Cheng F, Li Y, et al. In vitro modeling of human bocavirus 1 infection of polarized primary human airway epithelia. J Virol. (2013) 87:8907–10.

51. Jakiela B, Gielicz A, Plutecka H, Hubalewska-Mazga M, Mastalerz L, Bochenek G, et al. Th2-type cytokine-induced mucus metaplasia decreases susceptibility of human bronchial epithelium to rhinovirus infection. Am J Respir Cell Mol Biol. (2014) 51:229–41.
Frey et al. | Airway Epithelium in Asthma Pathogenesis

87. Dekker J, Rossen JWA, Bülter HA, Einerhand AWG. The MUC family: an obituary. Trends Biochem Sci. (2002) 27:126–31.

88. Raczewska DS, Tofafli F, Fletcher AA, Harper DN, Bochner BS, Janssen W, et al. Mucins and Their Sugars. Critical Mediators of Hypermucosity and Inflammation. Ann Am Thorac Soc. (2016) 13(Suppl. 1):598–9.

89. Hovenberg HW, Davies JR, Carlsle R. Different mucins are produced by the epithelial surface and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J. (1996) 318(Pt 1):319–24.

90. Wickström C, Davies JR, Eriksen GV, Veerman EC, Carlsle R. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J. (1998) 334(Pt 3):685–93.

91. Verdugo P. Mucin exocytosis. Am Rev Respir Dis. (1991) 144:S33–7.

92. Forstner G. Signal transduction, packaging and secretion of mucins. Annu Rev Physiol. (1995) 57:585–665. doi: 10.1146/annurev.ph.57.030195.003101

93. Ermund A, Meiss LN, Rodriguez-Pineiro AM, Bähr A, Nilsson HE, Trillo-Muyo S, et al. The normal trachea is cleaned by MUC5B mucin bundles from the submucosal glands coated with the MUC5AC mucin. Biochim Biophys Acta Mol Cell Biol Mem. (2017) 1922:331–37.

94. Ostedgaard LS, Moninger TO, McMenimen JD, Sawin NM, Parker CP, Thornell LM, et al. Gel-forming mucins form distinct morphologic structures in airways. Proc Natl Acad Sci USA. (2011) 108:6482–7.

95. Bustamante-Marín XM, Ostrowski LE. Cilia and mucociliary clearance. Cold Spring Harb Perspect Biol. (2017) 9:028241. doi: 10.1101/cshperspect.a028241

96. Bateman JR, Pavia D, Sheahan NF, Agnew JE, Clarke SW. Impaired tracheobronchial clearance in patients with mild stable asthma. Thorax. (1983) 38:463–7.

97. O’Riordan TG, Zwang J, Smaldone GC. Changes in mucociliary clearance during acute exacerbations of asthma. Am Rev Respir Dis. (1991) 143:993–7.

98. Thomas B, Rutman A, Hirst RA, Haldar P, Wardlaw AJ, Bankart J, et al. Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. J Allergy Clin Immunol. (2010) 126:722–7.e2.

99. Innes AL, Carrington SD, Thornton DJ, Kirkham S, Rousseau K, Dougherty JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and cell hyperplasia, and bronchial hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med. (1999) 160:1283–91.

100. Hoshino A, Tsuchi T, Matsuzaki J, Jinushi T, Ashino S, Teramura T, et al. STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyperresponsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation. Int Immunol. (2004) 16:1497–505.

101. Lokuolik J, Perret E, Willems T, Minty A, Parthoens E, Hocucine O, et al. IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells. J Clin Invest. (2001) 108:1817–24.

102. Kuperman DA, Lewis CC, Woodruff RM, Rodgers MW, Yang YH, Dolganov GM, et al. Dissecting asthma using focused transgenic modeling and functional genomics. J Allergy Clin Immunol. (2005) 116:3065–11.

103. Amishima M, Munakata M, Nasuha Y, Sato A, Takahashi T, Homma Y, et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Cell Mol Biol. (1998) 157:1907–12.

104. Takeyama K, Dabbagh K, Lee HM, Agustí C, Ueki JE, et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA. (1999) 96:3081–6.

105. Barbeau R, Paquet AC, et al. Expression of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. (2002) 8:885–9.

106. Whittaker L, Niu N, Temann U-A, Stoddard A, Flavell RA, Ray A, et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucins induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol. (2002) 27:593–602. doi: 10.1165/rcmb.4838

107. Kuperman DA, Lewis CC, Woodruff RM, Rodgers MW, Yang YH, Dolganov GM, et al. Dissecting asthma using focused transgenic modeling and functional genomics. J Allergy Clin Immunol. (2005) 116:3065–11.

108. Amishima M, Munakata M, Nasuha Y, Sato A, Takahashi T, Homma Y, et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Cell Mol Biol. (1998) 157:1907–12.

109. Takeyama K, Dabbagh K, Lee HM, Agustí C, Ueki JE, et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA. (1999) 96:3081–6.

110. Perras M, Pigny P, Copin M-C, Aube J-P, Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem. (2002) 277:32528–67.

111. Zhen G, Park SW, Nguyen LT, Rodgers MW, Barbeau R, Paquet AC, et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Cell Mol Biol. (1998) 157:1907–12.

112. Ordonez CL, Khashayar W, Wong HH, Ferrando R, Wu R, Hyde DM, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med. (2001) 163:517–23.

113. Doucet R, Boczkowski J, Jeanlottte L, Delacourt C. Cellular and molecular mechanisms of goblet cell metaplasia in the respiratory airways. Exp Lung Res. (2013) 39:207–16.

114. Temann UA, Prasad B, Gallup MW, Basbaum C, Ho SB, Flavell RA, et al. novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion. Am J Respir Cell Mol Biol. (1997) 16:471–8.

115. Grünig G, Warnock M, Wakkal AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. (1998) 282:2261–3.

116. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 13 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. (1998) 180:1307–20.

117. Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JAL: - 4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol. (1999) 162:633–47.

118. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. (2008) 121:685–91.
129. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. *J Allergy Clin Immunol.* (1997) 99:657–65.

130. Leonard C, Tormey V, Burke C, Poultier LW. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. *Am J Respir Cell Mol Biol.* (1997) 17:368–75.

131. Shimbara A, Christodouloupolus P, Soussi-Gounni A, Olicerstein N, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. *J Allergy Clin Immunol.* (2000) 105:108–15.

132. Danahay H, Pessotti AD, Coote J, Montgomery BE, Xia D, Wilson A, et al. Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung. *Cell Rep.* (2015) 10:239–52.

133. Chen G, Korthagen TR, Xu Y, Kitzmiller J, Wert SE, Maeda Y, et al. SPDEF regulates mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. *J Clin Invest.* (2009) 119:2914–24.

134. Park K-S, Korthagen TR, Bruno MD, Kitzmiller JA, Wan H, Wert SE, et al. SPDEF regulates goblet cell hyperplasia in the airway epithelium. *J Clin Invest.* (2007) 117:978–88.

135. Rajavuori P, Chen G, Xu Y, Kitzmiller JA, Korthagen TR, Whitsett JA. Airway epithelial SPDEF integrates goblet cell differentiation and pulmonary Th2 inflammation. *J Clin Invest.* (2015) 125:2021–31.

136. Wan H, Kaestner KH, Ang S-L, Ikegami M, Finkelman FD, Stahlman MT, et al. Foxa2 regulates alveolarization and goblet cell hyperplasia. *Development.* (2004) 131:953–64.

137. Vock C, Yildirim AO, Wagner C, Schlick S, Lunding LP, Lee CG, et al. Distal airways are protected from goblet cell metaplasia by diminished expression of IL-13 signalling components. *Clin Exp Allergy.* (2015) 45:1447–58.

138. Duszyk M. CFTR and lysozyme secretion in human airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol.* (2005) 332:L548–52.

139. Basbaum CB, Jany B, Finkbeiner WE. The serous cell. *J Exp Biol.* (1990) 52:97–113.

140. Chen J, Chen Z, Chintagari NR, Bhaskaran M, Jin N, Narasaraju T, et al. Alveolar type I cells protect rat lung epithelium from oxidative injury. *J Pathol.* (2006) 172:625–38.

141. Kim K-J, Malik AB. Protein transport across the lung epithelial barrier. *J Physiol Lung Cell Mol Physiol.* (2003) 284LC:247–59.

142. Mestecky J, Zikan J, Butler WT. Immunoglobulin A: presence of a common polypeptide chain different from function. *J Immunol.* (1971) 105:108–15.

143. Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Montag TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. *J Infect Dis.* (1996) 174:256–61.

144. Blumenthal T, Zickler CR, Georgakopoulos K, Montag TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. *Antimicrob Agents Chemother.* (1994) 38:2785–91.

145. Mazanec MB, Nedrud JG. Lamm ME. Immunoglobulin A monoclonal antibodies protect against Sendai virus. *J Virol.* (1987) 61:2624–6.

146. Winner I, Illi, Mack J, Weltzin R, Melanados J, Kraehenbuhl JP, Neutra MR. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridomas protects against Vibrio cholerae infection. *Infect Immun.* (1991) 59:977–82.

147. Michetti P, Mahan MJ, Slauch JM, Melanados J, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. *Infect Immun.* (1992) 60:1786–92.

148. Nickter FM, Michetti P, Winner LS III, Mack JA, Melanados J, Neutra MR. Analysis of the roles of antigipolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. *Infect Immun.* (1993) 61:5279–85.

149. Royle I, Roos A, Harvey DJ, Wormald MR, van Gilsjwansen J, Redwan E, et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. *J Biol Chem.* (2003) 278:20410–30.

150. Marshall LJ, Perks B, Ferkol T, Shute JK. IL-8 release constitutively by primary bronchial epithelial cells in culture forms an inactive complex with secretory component. *J Immunol.* (2001) 167:2816–23.

151. Wines BD, Hogarth PM. IgA receptors in health and disease. *Tissue Antigens.* (2006) 68:103–14.

152. Van Spriel AB, Leusen JHW, Ville H, Van De Winkel JG. Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA. *J Immunol.* (2002) 169:3813–6.

153. Barretes KR, Cooper KM, Drain KL, Kita H. Secretory IgA induces antigen-independent eosinophil survival and cytokine production without inducing effector functions. *J Allergy Clin Immunol.* (2005) 116:827–35.

154. Peebles RS Jr., Liu MC, Adkinson NF Jr., Lichtenstein LM, Hamilton RG. Rapweed-specific antibodies in bronchial lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation. *J Allergy Clin Immunol.* (1998) 101:265–73.

155. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ. IgA-induced eosinophil degranulation. *J Immunol.* (1989) 142:2393–400.

156. Chu VT, Beller A, Rausch S, Strandmark J, Zänker M, Arbach O, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. *Immunology.* (2014) 40:582–93.

157. Jung X, Wen T, Mingler MK, Caldwell JM, Wang YH, Chaplin DD, et al. IL-1β in eosinophil-mediated small intestinal homeostasis and IgA production. *Microbes Immunol.* (2015) 8:930–42.

158. Kobayashi K, Suzukiwa M, Watanabe K, Arakawa S, Igarashi S, Asari I, et al. Secretory IgA accumulated in the airspaces of idiopathic pulmonary fibrosis and promoted VEGF and IL-8 production by A549 cells. *Clin Exp Immunol.* (2019) 199:326–36. doi: 10.1111/cei.13390

159. Weltzin R, Lucia-Jandris P, Michetti P, Fields BN, Kraehenbuhl JP, Neutra MR. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. *J Cell Biol.* (1989) 108:1673–85.

160. Mantis NJ, Cheung MC, Chintalacharuvu KR, Rey I, Cortesby R, Neutra MR. Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. *J Immunol.* (2002) 169:1844–51.
173. Neutra MR, Pringault E, Kraehenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol. (1996) 14:275–300. doi: 10.1146/annurev.immunol.14.1.275

174. Kimura S. Molecular insights into the mechanisms of M-cell differentiation and transcytosis in the mucosa-associated lymphoid tissues. Anat Sci Int. (2018) 93:33–41. doi: 10.1111/j.1756-4661.2018.01252.x

175. He B, Xu W, Santini PA. Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T-cell independent immunoglobulin A2(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. (2007) 26:812–26.

176. Burnett D, Croker J, Stockley RA. Cells containing IgA subclasses in bronchi of subjects with and without chronic obstructive lung disease. J Clin Pathol. (1987) 40:1217–20.

177. Stoel M, Evenhuis WNH, Kroese FGM, Bos NA. Rat salivary gland reveals a more restricted IgA repertoire than ileum. Mol Immunol. (2008) 45:719–27.

178. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc. (2009) 6:525–9.

179. Peebles RS Jr., Hamilton RG, Lichtenstein LM, Schlosberg M, Liu MC, Prouet D, et al. Antigen-specific IgG and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy. (2001) 31:239–48.

180. Aghayan-Ugurluoglu R, Ball T, Vrtala S, Schweiger C, Kraft D, Valenta R. Dendritic cells express tight junction proteins and penetrate gut epithelial barriers. Anat Sci Int. (2009) 104:55–62. doi: 10.1016/j.ansci.2009.08.002

181. Nahm DH, Kim HY, Park HS. Elevation of specific immunoglobulin A in nasal secretions of house dust mite Dermatophagoides farinae in nasal secretions. Arerugi. (2005) 54:219–29. doi: 10.2336/arerugi.54.219

182. Hupin C, Rombaux P, Bowen H, Gould H, Lecocq M, Pilette C. Chronic inflammatory airway disease: the central role of the epithelium revisited. Clin Exp Allergy. (2016) 46:529–42.

183. Kouzaki H, O’Grady SM, Lawrence CB, Kita H. Proteases induce production of salivary immunoglobulin A and suppression of Dendriform phagocytes, pteronyssin-induced airway inflammation by local nasal immunotherapy. Int Arch Allergy Immunol. (2005) 138:161–8.

184. Cho ST, Hupin C, Pilette L, Lajemdi MZ. Chronic inflammatory airway diseases: the role of the epithelium revisited. Front Immunol. (2015) 5:151–15. doi: 10.3389/fimmu.2014.00235

185. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. (2012) 18:684–92.

186. Pouwels SD, Heijink IH, Hacken NHT, Vandenabeele P, Krysko DV, Nawijn MC, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. (2014) 7:215–26.

187. Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol. (2011) 45:189–201. doi: 10.1165/rcmb.2011-0011rt

188. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, et al. Antigen-specific IgE and IgA antibodies from clinical studies. Proc Natl Acad Sci USA. (2005) 102:2373–8. doi: 10.1073/pnas.0406836102

189. Lambrecht BN, Hammad H. The airway epithelium in asthma. Trends Immunol. (2011) 32:858–62.

190. Willart MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN. The airway epithelium in asthma. Annu Rev Immunol. (2009) 27:1124–60. doi: 10.1146/annurev.immunol.022608.111743

191. Willar MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN. The airway epithelium in asthma. Annu Rev Immunol. (2012) 30:252–30.

192. Lambrecht BN, Hammad H. Allergens and the airway epithelium response: gateway to allergic sensitization. J Allergy Clin Immunol. (2014) 134:499–507. doi: 10.1016/j.jaci.2014.06.036

193. Gohy ST, Hupin C, Pilette L, Lajemdi MZ. Chronic inflammatory airway diseases: the central role of the epithelium revisited. Clin Exp Allergy. (2016) 46:529–42.

194. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. (2004) 23:327–33.

195. Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol. (2011) 45:189–201. doi: 10.1165/rcmb.2011-0011rt

196. Luj-H-Y, Tsai J-J. Production of salivary immunoglobulin A and suppression of Dendriform phagocytes, pteronyssin-induced airway inflammation by local nasal immunotherapy. Int Arch Allergy Immunol. (2005) 138:161–8.

197. Lambrecht BN, Hammad H. The airway epithelium in asthma. Trends Immunol. (2011) 32:858–62.

198. Willart MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN. The airway epithelium in asthma. Annu Rev Immunol. (2009) 27:1124–60. doi: 10.1146/annurev.immunol.022608.111743

199. Lambrecht BN, Hammad H. Allergens and the airway epithelium response: gateway to allergic sensitization. J Allergy Clin Immunol. (2014) 134:499–507. doi: 10.1016/j.jaci.2014.06.036

200. Lambrecht BN, Hammad H. Airway epithelial cell receptors and signals, atopy and asthma. Clin Exp Allergy. (2014) 151:1–15. doi: 10.1016/j.clin.2013.12.003

201. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. (2012) 18:684–92.

202. Pouwels SD, Heijink IH, Hacken NHT, Vandenabeele P, Krysko DV, Nawijn MC, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. (2014) 7:215–26.

203. Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol. (2011) 45:189–201. doi: 10.1165/rcmb.2011-0011rt

204. Willard MAM, Lambrecht BN. The airway epithelium in asthma. Annu Rev Immunol. (2009) 27:1124–60. doi: 10.1146/annurev.immunol.022608.111743

205. Willard MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN, et al. Interleukin-1α controls allergic sensitization to inhaled allergen. J Immunol. (2010) 184:3535–44.

206. Willard MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. (2009) 15:410–6.

207. Kouzaki H, Hidaka T, Itoh M, Shimizu T. Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells. Am J Respir Cell Mol Biol. (2013) 49:741–50.

208. Tan AM, Chen H-C, Pochard P, Eisenbarth SC, Herrick CA, Bottomly HK, TLR4 signaling in stromal cells is critical for the initiation of allergic Th2 responses to inhaled antigen. J Immunol. (2010) 184:3535–44.

209. Willard MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. (2009) 15:410–6.

210. Kouzaki H, Hidaka T, Itoh M, Shimizu T. Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells. Am J Respir Cell Mol Biol. (2013) 49:741–50.

211. Willard MAM, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. (2009) 15:410–6.
217. Hill DA, Siracusa MC, Abt MC, Kim BS, Kobuley D, Kubo M, et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. *Nat Med.* (2012) 18:538–46.

218. Monticelli LA, Sonnenberg GF, Artis D. Innate lymphoid cells: critical regulators of allergic inflammation and tissue repair in the lung. *Curr Opin Immunol.* (2012) 24:284–9.

219. Regueiro V, Moranta D, Campos MA, Margareto J, Garmandia J, Bengochea JA. *Klebsiella pneumoniae* increases the levels of Toll-like receptors 2 and 4 in human airway epithelial cells. *Infect Immun.* (2009) 77:714–24.

220. Uehara A, Fujimoto Y, Fuku K, Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce antimicrobial peptides, but not proinflammatory cytokines. *Mol Immunol.* (2007) 44:3100–11.

221. Wang Q, Nagarkar DR, Bowman ER, Schneider D, Gosangi R, Lei J, et al. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. *J Immunol.* (2009) 183:6989–97.

222. Bertolusso R, Tian B, Zhao Y, Vergara L, Sabree A, Iwanaszko M, et al. Dynamic cross talk model of the epithelial innate immune response to double-stranded RNA stimulation: coordinated dynamics emerging from cell-level noise. *PLoS One.* (2014) 9:e93396. doi: 10.1371/journal.pone.0093396.

223. Groskrezt D, Monick MM, Powers LS, Yarovskyi TO, Look DC, Hunnghake GW. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. *J Immunol.* (2006) 176:1733–40.

224. Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, et al. Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. *J Immunol.* (2007) 178:3368–72.

225. Shornick LP, Wells AG, Zhang Y, Patel AC, Huang G, Takami K, et al. Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection. *J Immunol.* (2008) 180:3319–28.

226. Hsu AC-Y, Parsons K, Barr I, Lowther S, Middleton D, Hansbro PM, et al. Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. *J Immunol.* (2003) 171:6820–6.

227. Ibrahim ZA, Armour CL, Phipps S, Sukkar MB. RAGE and TLRs: relatives, friends or neighbours? *Mol Immunol.* (2013) 56:739–44.

228. Gao W, Li L, Wang Y, Zhang S, Adcock IM, Barnes PJ, et al. Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease? *Respir Res.* (2015) 20:72–92.

229. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Hirota JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D, et al. The MAPK/ERK1/2-pathway. *Lab Invest.*

230. Sedgwick JB, Quan SF, Calhoun WJ, Busse WW. Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: comparison with airway eosinophils. *J Allergy Clin Immunol.* (1995) 96:375–85.

231. Skibinski G, Lyons J, Bell J, Heaney LG, et al. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. *J Allergy Clin Immunol.* (2014) 133:1142–8.

232. Kato A, Favoreto S Jr., Avila PC, Schreiper RP. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. *J Immunol.* (2007) 178:1080–7.

233. Grass D, Chanez P, Vachier I, Petit A, Bourdin A. Bronchial epithelium as a target for innovative treatments in asthma. *Pharmacol Ther.* (2013) 140:290–305. doi: 10.1016/j.pharmthera.2013.07.008.

234. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. *J Immunol.* (2010) 184:6568–74.

235. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier integrity. *Nat Immunol.* (2010) 11:289–93.

236. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. *J Immunol.* (2010) 184:6568–74.

237. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma allergy. *Respirology.*

238. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 17 years. *Lancet.* (1999) 354:541–5.

239. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, et al. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. *J Allergy Clin Immunol.* (2014) 133:1142–8.

240. Halim TYF, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. *Immunity.* (2012) 36:451–63.

241. Turner RB, Lee W-M. Rhinovirus. 3rd ed.

242. Barnett SBL, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. *J Allergy Clin Immunol.* (2011) 127:145–52.

243. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. *Am J Respir Crit Care Med.* (2000) 162:667–72.

244. hansel TT, Johnston SL, Openshaw PJ. Microbes and mucosal immune responses in asthma. *Lancet.* (2013) 381:861–73.

245. Friedlander SL, Busse WW. The role of rhinovirus in asthma exacerbations. *J Allergy Clin Immunol.* (2011) 127:145–52.

246. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma allergy. *Respirology.*

247. Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* (2015) 192:362–70.

248. Webering S, Lunding LP, Vock C, Schröder A, Gaede KI, Herzmann C, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. *J Allergy Clin Immunol.* (2007) 119:1105–10.

249. Turn RB, Lee W-M. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol.* (2005) 116:571–7.

250. Persis F, Hoogsteden HC, Coyle AJ, Lambrecht BN, Hammad H. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting TH2 cells and inducing airway inflammation. *Allergy.* (2009) 64:995–1002. doi: 10.1111/j.1398-9995.2009.02095.x.
258. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Dijkeng A, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. *Science.* (2009) 324:55–9.

259. Tomassini JE, Graham D, DeWitt CM, Lineberger DW, Rodkey JA, Colonnio RJ. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. *Proc Natl Acad Sci USA.* (1989) 86:4907–11.

260. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlows CW, et al. The major human rhinovirus receptor is ICAM-1. *Cell.* (1989) 56:839–47.

261. Colonnio RJ, Condra JH, Mizutani S, Callahan PL, Davies ME, Murcko MA. Evidence for the direct involvement of the rhinovirus canyon in receptor binding. *Proc Natl Acad Sci USA.* (1988) 85:5449–53.

262. Suzuki T, Yamaya M, Kamanaka M, Jia YX, Nakayama K, Hosoda M, et al. Type 2 rhinovirus infection of cultured human tracheal epithelial cells: role of LDL receptor. *Am J Physiol Lung Cell Mol Physiol.* (2001) 280:L409–20.

263. Mosser AG, Brockman-Schneider R, Aminova S, Burchell L, Sedgwick JB, Busse WW, et al. Similar frequency of rhinovirus-infectible cells in the lower and upper airway epithelium. *J Infect Dis.* (2002) 185:734–43.

264. Olson NH, Kolatkar PR, Oliveira MA, Cheng RH, Greve JM, McClelland A, et al. Structure of a human rhinovirus complexed with its receptor molecule. *Proc Natl Acad Sci USA.* (1993) 90:507–11.

265. Vlasak M, Roivainen M, Reithmayer M, Goesler I, Laine P, Snyers L, et al. Interleukin-11: stimulation and regulation of innate immune function in response to virus infection. *Virulence.* (2011) 2:22–9.

266. Einarsson O, Geba GP, Zhu Z, Landry M, Elias JA. Interleukin-11: stimulation and regulation of innate immune function in response to virus infection. *Virulence.* (2011) 2:22–9.

267. Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leir SH, Fraenkel DJ, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. *J Immunol.* (2015) 194:5615–25.

268. Slater L, Bartlett NW, Haas JJ, Zhu J, Message SD, Walton RP, et al. Tumstatin fragment selectively inhibits neutrophil infiltration in experimental asthma exacerbation. *Clin Exp Allergy.* (2018) 48:1483–93. doi: 10.1111/cea.13236.

269. Gaggar A, Jackson PL, Noerager BD, O’Reilly PJ, McQuaid DB, Rowe SM, et al. Novel proteolytic cascade generates an extracellular matrix-derived chemooattractant in chronic neutrophilic inflammation. *J Immunol.* (2008) 180:5662–9.

270. McErlean P, Favoretto S, Costa FF, Shen J, Quraishi J, Biyasheva A, et al. Human rhinovirus infection causes different DNA methylation changes in nasal epithelial cells from healthy and asthmatic subjects. *BMC Med Genomics.* (2009) 2:12.

271. Harig B, Juniper B, Beasley R. Rhinovirus infections change DNA methylation and mRNA expression in human alveolar epithelial cells. *PLoS One.* (2013) e0205275. doi: 10.1371/journal.pone.0205275.

272. Reza Etemadi M, Ling K-H, Zainal Abidin S, Chee H-Y, Sekawi Z. Gene expression patterns induced at different stages of rhinovirus infection in human alveolar epithelial cells. *PLoS One.* (2012) 13:e0176947. doi: 10.1371/journal.pone.0176947.

273. Burgess JK, Weckmann M. Tumstatins and the lungs. *Pharmacoool Ther.* (2012) 134:317–37.

274. Patel DF, Peiró T, Shoemark A, Akhtar S, Walker SA, Graibe AM, et al. An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness. *Sci Transl Med.* (2010) 10:eaaq0693. doi: 10.1126/scitranslmed.aap0693.

275. Mills IT, Schwenzer A, Marsh EK, Sabroe I, Midwood KS, et al. Airway Epithelial Cells Generate Pro-inflammatory Tenascin-C and Small Extracellular Vesicles in Response to TRIM Stimuli and Rhinovirus Infection. *Front Immunol.* (2019) 10:1987.

276. Pech M, Weckmann M, König JR, Franke A, Heinsen F-A, Oliver B, et al. Rhinovirus infections change DNA methylation and mRNA expression in children with asthma. *PLoS One.* (2013) 190.e0205275. doi: 10.1371/journal.pone.0205275.

277. Millis JT, Schwenzer A, Marsh EK, Sabroe I, Midwood KS, et al. Airway Epithelial Cells Generate Pro-inflammatory Tenascin-C and Small Extracellular Vesicles in Response to TRIM Stimuli and Rhinovirus Infection. *Front Immunol.* (2019) 10:1987.

278. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. *Science.* (2009) 324:55–9.

279. Mills IT, Schwenzer A, Marsh EK, Sabroe I, Midwood KS, et al. Airway Epithelial Cells Generate Pro-inflammatory Tenascin-C and Small Extracellular Vesicles in Response to TRIM Stimuli and Rhinovirus Infection. *Front Immunol.* (2019) 10:1987.

280. Pech M, Weckmann M, König JR, Franke A, Heinsen F-A, Oliver B, et al. Rhinovirus infections change DNA methylation and mRNA expression in children with asthma. *PLoS One.* (2013) e0205275. doi: 10.1371/journal.pone.0205275.
298. Brand S, Kesper DA, Teich R, Kilic-Niebergall E, Pinkenburg O, Bothur E, et al. DNA methylation of TH1/TH2 cytokine genes affects sensitization and progress of experimental asthma. *J Allergy Clin Immunol.* (2012) 129:1602–10.e6.

299. Brand S, Teich R, Dicke T, Harb H, Yildirim AO, Tost J, et al. Epigenetic regulation in murine offspring as a novel mechanism for transmaternal asthma protection induced by microbes. *J Allergy Clin Immunol.* (2011) 128:618–25.

300. Jain-Vora S, Wert SE, Temann UA, Rankin JA, Whitsett JA. Interleukin-4 alters epithelial cell differentiation and surfactant homeostasis in the postnatal mouse lung. *Am J Respir Cell Mol Biol.* (1997) 17: 541–51.

301. van Wetering S, Zuyderduyn S, Ninaber DK, van Sterkenburg MAJA, Rabe KF, Hiemstra PS. Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. *Mol Immunol.* (2007) 44:803–11.

302. Kikuchi T, Shively JD, Foley JS, Drazen JM, Tschumperlin DJ. Differentiation-dependent responsiveness of bronchial epithelial cells to IL-4/13 stimulation. *Am J Physiol Lung Cell Mol Physiol.* (2004) 287:L119–26.

303. Zuyderduyn S, Ninaber DK, Schrupp FA, van Sterkenburg MA, Verhoosel RM, Prins FA, et al. IL-4 and IL-13 exposure during mucociliary differentiation of bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial peptides. *Respir Res.* (2011) 12:59.

304. Jakiela B, Gielicz A, Plutecka H, Hubalewska M, Mastalerz L, Bochenek G, et al. Eicosanoid biosynthesis during mucociliary and mucous metaplastic differentiation of bronchial epithelial cells. *Prostaglandins Other Lipid Mediat.* (2013) 106:116–23.

305. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, et al. TH2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. *Allergy.* (2015) 70:910–20.

306. Rochlitzer S, Hoymann H-G, Müller M, Braun A. U-BIOPRED consortium. No exacerbation but impaired anti-viral mechanisms in a rhinovirus-chronic allergic asthma mouse model. *Clin Sci.* (2014) 126:55–65. doi: 10.1042/ cs20130174

307. Bot A, Holz A, Christen U, Wolfe T, Temann A, Flavell R, et al. Local IL-4 expression in the lung reduces pulmonary influenza-virus-specific secondary cytotoxic T cell responses. *Virology.* (2000) 269:66–77. doi: 10.1006/viro.2000.0187.

308. Zissler UM, Ulrich M, Jakwerth CA, Rothkirch S, Guerth F, Weckmann M, et al. Biomatrix for upper and lower airway biomarkers in patients with allergic asthma. *J Allergy Clin Immunol.* (2018) 142:1980–3.

309. Zissler UM, Jakwerth CA, Guerth FM, Pechtold L, Aguilar-Pimentel JA, Dietz K, et al. Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT. *EBioMedicine.* (2018) 36:475–88.

310. Tan LH, Bahmed K, Lin C-R, Marchetti N, Bolla S, Criner GJ, et al. The cytoprotective role of DJ-1 and p65 NFκB type II cell injury and emphysema. *Sci Rep.* (2018) 8:3555.

311. Boucherat O, Chakir J, Jeannotte L. The loss of Hoxa5 function promotes Notch-dependent goblet cell metaplasia in lung airways. *Biol Open.* (2012) 1:677–91.

312. Zissler UM, Esser-von Bieren J, Jakwerth CA, Chaker AM, Schmidt-Weber CB. Current and future biomarkers in allergic asthma. *Allergy.* (2016) 71:475–94.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Frey, Lunding, Ehlers, Weckmann, Zissler and Wegmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.